BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2021 11:08:13 AM | Browse: 492 | Download: 566
 |
Received |
|
2021-02-08 05:33 |
|
Peer-Review Started |
|
2021-02-08 05:37 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-29 21:27 |
|
Revised |
|
2021-04-09 23:26 |
|
Second Decision |
|
2021-07-09 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-07-09 12:05 |
|
Articles in Press |
|
2021-07-09 12:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-08-10 05:02 |
|
Publish the Manuscript Online |
|
2021-08-14 11:08 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alexa R Weingarden, Samuel J S Rubin and John Gubatan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alexa R Weingarden, MD, PhD, Academic Fellow, Consultant Physician-Scientist, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, 420 Broadway Street, Pavilion D, 2nd Floor, Redwood City, CA 94063, United States. aweingar@stanford.edu |
| Key Words |
Immune checkpoint inhibitors; Cytotoxic T-lymphocyte antigen 4; Programmed cell death protein-1; Inflammatory bowel disease; Gastrointestinal cancer |
| Core Tip |
Immune checkpoint inhibitor-mediated colitis and diarrhea (IMC) is a common immune-related adverse event with immune checkpoint inhibitor (ICI) therapy. The risk of IMC is most strongly associated with type of ICI used, but race, malignancy, and vitamin D use may also contribute to the risk of developing IMC. IMC incidence in gastrointestinal cancers appears comparable to other malignancies, but this is hampered by lack of a consistent definition for IMC and confounding by contemporaneous chemotherapy. Although patients with inflammatory bowel disease (IBD) are often excluded from treatment with ICI, available data suggest that they have increased risk of diarrhea and/or colitis compared to patients without IBD. |
| Publish Date |
2021-08-14 11:08 |
| Citation |
Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i8.772 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
